Table 1.
Characteristic of AML primary cells and cell lines.
| Primary AML | FAB | WHO classification | Age | Blasts | ABT-199 | A1331852 | S63845 |
|---|---|---|---|---|---|---|---|
| [Y] | [%] | EC50 [µM] | EC50 [µM] | EC50 [µM] | |||
| 30* | M5 | 75 | 75 | >10 | >10 | 0.06 | |
| 31* | AML without maturation | 83 | 87 | 0.38 | >10 | 0.1 | |
| 32* | 47 | 34 | 0.04 | >10 | 0.22 | ||
| 34 | AML with NPM1 mutation | 58 | 91 | >10 | N.D. | N.D. | |
| 35 | sec. AML after MDS/MPN, Overlap/AML with MDS-related changes | 59 | 39 | >10 | >10 | >10 | |
| 38* | M1 | AML without maturation | 71 | 83 | 0.05 | >10 | 1 |
| 42* | M4 | AML with NPM1 mutation | 57 | 25 | >10 | >10 | 0.76 |
| 43* | M4 | AML with NPM1 mutation | 73 | 81 | >10 | >10 | 0.14 |
| 45 | AML, NOS | 33 | 74 | >10 | >10 | 0.1 | |
| 47* | M1 | AML, NOS | 74 | 71 | >10 | >10 | >10 |
| 48 | M4 | AML with MDS-related changes | 58 | 40 | >10 | >10 | >10 |
| 55 | secondary AML after MDS | 79 | 25 | 2.2 | 9 | 1.1 | |
| 56 | M4 | secondary AML after MDS | 75 | 25 | 0.05 | 4 | 2.5 |
| 59* | M1 | AML with recurrent genetic modifications | 76 | 71 | >10 | >10 | 0.21 |
| 60 | M5 | AML, NOS | 22 | 95 | 0.07 | >10 | 0.007 |
| Cell lines | |||||||
| MOLM-13 | M5a | 0.083 | >10 | 0.05 | |||
| ML-2 | M4 | 0.11 | 6.8 | 0.31 | |||
| HL-60 | M2 | 3 | >10 | 1.98 | |||
| KG-1 | − | 4 | >10 | 0.49 | |||
| MV4-11 | M5 | 0.013 | 3.3 | 0.02 | |||
| KASUMI-1 | M2 | 0.77 | 1.8 | 0.15 | |||
| NB4 | M3 | 3 | >10 | 0.06 | |||
| PLB985 | M2 | 3 | >10 | 0.22 | |||
| THP-1 | M5 | 3 | >10 | 0.1 | |||
| MONO-MAC-6 | M5 | 4 | 5.6 | 0.072 | |||
| OCI-AML3 | M4 | >10 | >10 | 1.5 | |||
EC50 values to BH3-mimetics were calculated from combined Annexin-V/FITC and anti-CD45/APC staining and flow cytometry (for primary cells) and CellTiter-Glo viability assay (for cell lines) by non-linear regression analysis using GraphPad prism. For primary AML samples, data were derived from either freshly isolated AML blasts or from previously frozen samples (*). FAB French-American-British classification system, NOS Not Otherwise Specified, MDS Myelodysplastic syndrome, ND Not determined